Announcement on Convening Performance Briefing for 2025 and Q1 2026
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
Announcement on Convening Performance Briefing for 2025 and Q1 2026
Filed with SSE · · 2 pages · Chinese
Release
Zhejiang CONBA Pharmaceutical Co., Ltd. on 6ix
Earlier from Zhejiang CONBA Pharmaceutical
- Announcement on Resolutions of the 2025 Annual General Meeting
- Announcement on Obtaining Drug Registration Certificate for Blonanserin Tablets by its Subsidiary
- Report for Q1 2026
- Announcement on Subsidiary Obtaining Drug Registration Certificate for Telmisartan Amlodipine Tablets (III)
- Announcement on Voluntary Exercise Results of Stock Option Incentive Plan in Q1 2026 and Share Changes
Later from Zhejiang CONBA Pharmaceutical
- Announcement on the Public Listing and Transfer of 100% Equity Interest in Dongyang Conba
- Announcement on Implementation of Dividend Distribution for 2025
- Announcement on Resolutions of the 18th (Extraordinary) Meeting of the 11th Board of Directors
- Announcement on Self-exercise Results of Stock Option Incentive Plan and Share Changes for Q2 2026
- Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2026
Follow Zhejiang CONBA Pharmaceutical into a list and get an email when it puts out news.
Follow Zhejiang CONBA Pharmaceutical